Zoligratinib

DB12903InvestigationalSmall molecule

Ch5183284 has been used in trials studying the treatment of Solid Tumours.

Mechanism: Pharmacologically active on Fibroblast growth factor receptor 3, Fibroblast growth factor receptor 2, and Fibroblast growth factor receptor 1
Curator reviewed
Formula / weight: C₂₀H₁₆N₆O · 356.389 g/mol (avg)
Code names: CH-5183284 · DEBIO-1347

Resolves to

Compound

Structure

InChIKeyBEMNJULZEQTDJY-UHFFFAOYSA-NSMILESCC1=NC2=CC=C(C=C2N1)N1N=CC(C(=O)C2=CC3=CC=CC=C3N2)=C1N

Targets

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zoligratinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.